Moderna Aktie
| 39,36USD | -0,20USD | -0,51% |
WKN DE: A2N9D9 / ISIN: US60770K1079
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 89,18 |
| Baillie Gifford & Co. | 11,86 |
| Baillie Gifford & Co. | 11,03 |
| The Vanguard Group, Inc. | 10,14 |
| Vanguard Group, Inc. (Subfiler) | 10,07 |
| Stéphane Bancel, MBA | 5,48 |
| State Street Corp. | 4,38 |
| Robert S. Langer, Ph.D | 2,99 |
| Fidelity Management & Research Co. LLC | 2,85 |
| Vanguard Total Stock Market ETF | 2,85 |
| BlackRock Fund Advisors | 2,70 |
| Vanguard 500 Index Fund | 2,33 |
| Scottish Mortgage Investment Trust Plc | 2,24 |
| Vanguard International Growth Fund | 2,22 |
| Invesco QQQ Trust | 1,98 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 830 | 1 300 | 2 700 | 3 900 | 5 600 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,07 | 0,62 | 6,82 | 4,90 | 1,22 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 129 | 6 298 | 16 071 | 13 431 | 10 325 |
| Summe Anlagevermögen | 461 | 1 039 | 8 798 | 12 656 | 8 101 |
| Summe Aktiva | 1 589 | 7 337 | 24 869 | 26 087 | 18 426 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 415 | 4 775 | 10 724 | 6 964 | 4 572 |
| Summe Eigenkapital | 1 175 | 2 561 | 14 145 | 19 123 | 13 854 |
| Summe Passiva | 1 589 | 7 337 | 24 869 | 26 087 | 18 426 |
Adresse
| 325 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 714-6500 |
| Internet | http://www.modernatx.com |
Management
|
Brad Miller
Chief Information Officer |
|
Charbel Haber
Senior Vice President-Regulatory Science |
|
David Mark Rubenstein
Director |
|
Elizabeth E. Tallett
Independent Director |
|
Elizabeth G. Nabel
Independent Director |
|
Francois Nader
Independent Non-Executive Director |
|
Jacqueline Miller
Chief Medical Officer |
|
James M. Mock
Chief Financial Officer |
|
Jerh Collins
Chief Technical Operations & Quality Officer |
|
John Lepore
Senior Vice President-Government Engagement |
|
Jonathan Hoggatt
Director-Hematology |
|
José M. Vega
Chief Safety Officer |
|
Kate Cronin
Chief Brand Officer |
|
Lavina A. Talukdar
Senior Vice President & Head-Investor Relations |
|
Melanie Ivarsson
Chief Development Officer |
|
Noubar B. Afeyan
Chairman |
|
Patrick Norman Bergstedt
Senior Vice President-Commercial Vaccines |
|
Paul L. Sagan
Independent Non-Executive Director |
|
Paula Hammond
Scientific Advisory Board |
|
Rose Loughlin
Executive Vice President-Research |
|
Sandra J. Horning
Independent Director |
|
Shah Abbas Hussain
Director |
|
Shannon Thyme Klinger
Secretary & Chief Legal Officer |
|
Stephen Hoge
President |
|
Stéphane Bancel
Chief Executive Officer & Director |
|
Tracey Franklin
Chief People & Digital Technology Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
